Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 267

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type

Open access
Unizony, Sebastian, Villarreal, Miguel, Miloslavsky, Eli M, Lu, Na, Merkel, Peter A, Spiera, Robert, Seo, Philip, Langford, Carol A, Hoffman, Gary S, Kallenberg, CG M, St. Clair, E William, Ikle, David, Tchao, Nadia K, Ding, Linna, Brunetta, Paul, Choi, Hyon K, Monach, Paul A, Fervenza, Fernando, Stone, John H, Specks, Ulrich · 2016 · Annals of the Rheumatic Diseases

Abstract

Objective To evaluate whether the classification of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) according to ANCA type (anti-proteinase 3 (PR3) or anti-myeloperoxidase (MPO) antibodies) predicts treatment response. Methods Treatment responses were assessed among patients enrolled in the Rituximab in ANCA-associated Vasculitis trial according to both AAV diagnosis (granulomatosis with polyangiitis (GPA)/microscopic polyangiitis (MPA)) and ANCA type (PR3-AAV/MPO-AAV). Complete remission (CR) was defined as disease activity score of 0 and successful completion of the prednisone taper. Results PR3-AAV patients treated with rituximab (RTX) achieved CR at 6 months more frequently than did those randomised to cyclophosphamide (CYC)/azathioprine (AZA) (65% vs 48%; p=0.04). The OR for CR at 6 months among PR3-AAV patients treated with RTX as opposed to CYC/AZA was 2.11 (95% CI 1.04 to 4.30) in analyses adjusted for age, sex and new-onset versus relapsing disease at baseline. PR3-AAV patients with relapsing disease achieved CR more often following RTX treatment at 6 months (OR 3.57; 95% CI 1.43 to 8.93), 12 months (OR 4.32; 95% CI 1.53 to 12.15) and 18 months (OR 3.06; 95% CI 1.05 to 8.97). No association between treatment and CR was observed in the MPO-AAV patient subset or in groups divided according to AAV diagnosis. Conclusions Patients with PR3-AAV respond better to RTX than to CYC/AZA. An ANCA type-based classification may guide immunosuppression in AAV. Trial registration number NCT00104299; post-results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2015-208073

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 267

Metadata

Authors
Unizony, S., Villarreal, M., Miloslavsky, E. M., Lu, N., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. M., St. Clair, E. W., Ikle, D., Tchao, N. K., Ding, L., Brunetta, P., Choi, H. K., Monach, P. A., Fervenza, F., Stone, J. H., & Specks, U.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2016-06
Volume
75
Issue
6
Pages
1166-1169
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2266467924
Cited by
267
References
20
FWCI
9.99
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. https://app.cochat.ai/papers/10.1136/annrheumdis-2015-208073
The paper
Unizony, S., Villarreal, M., Miloslavsky, E. M., Lu, N., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. M., St. Clair, E. W., Ikle, D., Tchao, N. K., Ding, L., Brunetta, P., Choi, H. K., Monach, P. A., Fervenza, F., Stone, J. H., & Specks, U. (2016). Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2015-208073

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.